Alvine Pharmaceuticals, Inc. Announces Issuance of US Patents for Enzyme Use in Celiac Disease
5/18/2011 9:45:42 AM
SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine’s core technology. These patents cover gluten degradation with gluten-specific proteases, methods for identifying proteases useful in degrading gluten and reagents for diagnosing celiac disease. Alvine has an exclusive worldwide license to these patents from Stanford University.
comments powered by